HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Phio Pharma (NASDAQ:PHIO) with a maintained price target of $4.

May 14, 2024 | 10:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharma's Buy rating and $4 price target have been reiterated by HC Wainwright & Co., indicating continued analyst confidence in the company's potential.
The reiteration of a Buy rating and a specific price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This can positively influence investor sentiment and potentially lead to a short-term increase in stock price, especially if the market perceives the analysis as a strong endorsement of the company's value and future prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100